4basebio PLC
4BB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | -0.23 | -0.28 | -0.07 |
| FCF Yield | -7.76% | -9.15% | -7.60% | -5.61% |
| EV / EBITDA | -12.70 | -12.41 | -15.98 | -21.18 |
| Quality | ||||
| ROIC | -28.18% | -73.61% | -47.92% | -23.03% |
| Gross Margin | 67.52% | 67.19% | 89.18% | 79.59% |
| Cash Conversion Ratio | 0.87 | 0.81 | 0.91 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 51.56% | 14.40% | -16.60% | 18.72% |
| Free Cash Flow Growth | -60.60% | -15.40% | -56.28% | -127.26% |
| Safety | ||||
| Net Debt / EBITDA | 1.77 | -1.01 | 0.19 | 2.44 |
| Interest Coverage | -16.01 | -26.66 | -65.62 | -31.21 |
| Efficiency | ||||
| Inventory Turnover | 0.81 | 0.50 | 0.22 | 0.44 |
| Cash Conversion Cycle | -1,479.39 | -718.78 | -4,419.73 | -992.43 |